SCHEMBL3383806

SCHEMBL3383806

Cc1nc(C(N)=O)sc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 2/20 0.36
IKBKB O14920 1/20 0.34
LIMK1 P53667 1/20 0.34
LMNA P02545 2/20 0.33
F2 P00734 1/20 0.33
SCN9A Q15858 1/20 0.32
KDM4E B2RXH2 2/20 0.31
NPC1 O15118 2/20 0.31
MAPT P10636 2/20 0.31
GAA P10253 1/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
RAB9A P51151 2/20 0.31
PIM3 Q86V86 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677906 0.78 NOS1 (0.44) ALDH1A1POLBIKBKBLIMK1LMNA
SCHEMBL4769662 0.75 IKBKB (0.34) ALDH1A1HPGDTSHRIKBKBLIMK1
SCHEMBL16751925 0.75 ALDH1A1 (0.34) ALDH1A1HPGDTSHRIKBKBLIMK1
SCHEMBL3000943 0.73 SMN1; SMN2 (0.45) ALDH1A1HPGDTSHRPOLBLMNA
SCHEMBL31675965 0.73 ALDH1A1 (0.55) ALDH1A1HPGDTSHRPOLBIKBKB
SCHEMBL1938667 0.72 CA12 (0.37) POLBIKBKBLIMK1KDM4ENPC1
SCHEMBL2676992 0.72 KMT2A (0.44) ALDH1A1HPGDIKBKBLIMK1LMNA
SCHEMBL5875654 0.72 FBP1 (0.35) ALDH1A1IKBKBLIMK1CYP1A2
SCHEMBL5875559 0.71 ALDH1A1 (0.33) ALDH1A1IKBKBLIMK1MAPT
SCHEMBL5875630 0.71 IKBKB (0.32) ALDH1A1TSHRIKBKBLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841334-B2 Compounds as cannabinoid receptor ligands and uses thereof ABBVIE INC. (US) 2014-09-23 US disclosed
US-8546583-B2 Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide ABBVIE INC. (US) 2013-10-01 US disclosed
EP-2222165-B1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC (US) 2013-07-31 EP disclosed
EP-2222165-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-09-01 EP disclosed
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-04-15 US disclosed
WO-2009067613-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-05-28 WO disclosed
US-20080058335-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC. 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 ALDH1A1 898/4885HPGD 2262/4885TSHR 332/4885
US-20080058335-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 ALDH1A1 914/4885HPGD 2066/4885TSHR 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.